Shows
JNNP PodcastCyclophosphamide for myasthenia gravis: a comeback?Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this podcast suggests that lower doses of cyclophosphamide can be effective and safe in people with MG, including older age. JNNP's podcast editor, Saima Chaudhry, is joined by Professor Carolina Barnett-Tapia, University of Toronto, University Health Network, who authors the editorial comment 'Cyclophosphamide for myasthenia gravis: a comeback?'(https://jnnp.bmj.com/content/95/12/1095).
The original paper is also free to access: https://jnnp.bmj.com/content/95/12/1096.
Please subscribe t...2025-04-1737 minJNNP PodcastManagement methods for acute ischaemic strokeThe effectiveness of endovascular treatment (EVT) in cases of acute ischaemic stroke caused by distal medium vessel occlusion (DMVO) is still unclear. A study in the JNNP assessed the safety and effectiveness of EVT in comparison to the best medical management for DMVO. Podcast host Dr. Saima Chaudhry¹ spoke to some of the paper's authors, Dr. Adam Dmytriw², Dr. Vivek Yedavalli³ and Dr. Hamza Salim³.
Read the paper: Endovascular therapy versus best medical management in distal medium middle cerebral artery acute ischaemic stroke: a multinational multicentre propensity score-matched study
1. Warren Alpert Medica...2025-02-1326 minJNNP PodcastDistinguishing autoimmune nodopathies from CIDP, with Dr. Ruth Huizinga and Dr. Maarten TitulaerChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) can be difficult to distinguish from autoimmune nodopathy. In this podcast, Dr. Saima Chaudhry (1) is joined from the Netherlands by Dr. Ruth Huizinga (2) and Dr. Maarten Titulaer (3), to discuss their article, "Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort". They start with explaining what an autoimmune nodopathy really is, patient features to look out for, and the typical testing process for identifying CIDP.
(1) Warren Alpert Medical School, Brown University, Rhode Island, USA
(2) Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2024-07-1538 minJNNP PodcastNutritional peripheral neuropathies, with Dr. Alexander RossorThe cause of a nutritional neuropathy may not always be obvious when first examining a patient. Restrictive diets with roots in religious practices or personal preferences will be less familiar to neurologists than issues involving bariatric surgery or diseases of malabsorption, and can present as being not overtly malnourished. A recent review in JNNP details links between B-vitamin deficiencies and peripheral neuropathy, and discusses historical trends in the occurrence of nutritional neuropathies. The review's last author, Dr. Alexander Rossor (1), joins host Dr. Saima Chaudhry (2) to talk through how to approach this diagnosis.
Read the paper h...2024-04-1739 minJNNP PodcastDistinguishing primary from functional ticsHow often do movement disorder specialists agree when classifying tics? A recent study published in JNNP explores this question with a two-stage approach, seeking a diagnosis from experts first based on video evidence alone and then following the provision of additional clinical data. The study's last author, Dr. Christos Ganos (1), joins host Dr. Saima Chaudhry (2) to discuss the results.
Read the paper here: "Distinguishing functional from primary tics: a study of expert video assessments"
Related links:
European Society for the Study of Tourette Syndrome 2022 criteria for clinical diagnosis of fun...2024-02-1940 minJNNP PodcastNitrous Oxide AbuseWith the UK government announcing plans to make recreational use of nitrous oxide illegal, JNNP podcast host Dr. Saima Chaudhry (1) is joined by London-based neurologist Dr. Alastair Noyce (2)(3) to examine the findings of his group's recently published research paper, "Nitrous oxide-induced myeloneuropathy: a case series". Read the paper here: https://jnnp.bmj.com/content/94/9/681
Related links:
https://www.gov.uk/government/news/nitrous-oxide-to-be-illegal-by-end-of-the-year
(1) Warren Alpert Medical School, Brown University, Rhode Island, USA
(2) Barts Health NHS Trust, London, UK
(3) Preventive Neurology Unit, Centre for Prevention, Diagnosis and Detection, Faculty of Medicine and D...2023-09-2227 minJNNP PodcastBrain Fog DemystifiedSocial media platforms and clinical patient encounters are abundant in references to brain fog, but how much is it really understood? In this episode, JNNP's podcast host, Dr. Saima Chaudhry (1), speaks with Dr. Laura McWhirter (2) about her recently published article, "What is Brain Fog?"and how further understanding of this can help to better treat patients.
You can read the paper at the following link: https://jnnp.bmj.com/content/94/4/321
(1) Warren Alpert Medical School, Brown University, Rhode Island, USA
(2) Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
...2023-08-0830 minJNNP PodcastA roadmap to ALS prevention: strategies and prioritiesIn this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors for ALS risk, and to identify high-risk groups for further study.
Note: The genetic therapy referred to as Tofersen, under review at the time of...2023-06-1538 min
BMJ talk medicineMOGAD: Definition, diagnosis and treatmentIn this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Matteo Gastaldi (2) about Myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD for short. A multi-centre retrospective study, "Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD", was recently published in JNNP, and Dr. Gastaldi is its first author. Listen to this podcast to learn what MOGAD is, its differential diagnosis and the potential pathogenesis. Plus some discussion of the use of MOG titres in predicting relapse of the disease. You can read the paper at the following link: https://jnnp.bmj.com/content/94/3/201
(1) Warren...2023-05-1521 minJNNP PodcastMOGAD: Definition, diagnosis and treatmentIn this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Matteo Gastaldi (2) about Myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD for short. A multi-centre retrospective study, "Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD", was recently published in JNNP, and Dr. Gastaldi is its first author. Listen to this podcast to learn what MOGAD is, its differential diagnosis and the potential pathogenesis. Plus some discussion of the use of MOG titres in predicting relapse of the disease. You can read the paper at the following link: https://jnnp.bmj.com/content/94/3/201 2023-05-1521 min